HEPION PHARMACEUTICALS, INC. Interest Income (Expense), Nonoperating, Net
HEPION PHARMACEUTICALS, INC. (HEPA) reported Interest Income (Expense), Nonoperating, Net of $6.24 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-13
- HEPION PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $6.24K, a 28.30% increase year-over-year.
- HEPION PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was -$2.13K.
- HEPION PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was -$12.58K.
- HEPION PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $8.12K.
- HEPION PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for fiscal 2025 was -$24.41K.
- HEPION PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for fiscal 2024 was -$1.25M.
- HEPION PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for fiscal 2023 was -$9.46K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.24K 10-Q · filed 2026-08-13 | $4.11K 10-Q · filed 2026-08-13 | -$8.46K derived: sum of 3 quarters · filed 2026-08-13 | -$347.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.13K 10-Q · filed 2026-05-14 | -$14.71K derived: sum of 2 quarters · filed 2026-05-14 | -$6.59K derived: sum of 3 quarters · filed 2026-05-14 | -$1.72K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$12.58K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$4.46K derived: sum of 2 quarters · filed 2026-03-12 | $405.00 derived: sum of 3 quarters · filed 2026-08-13 | -$24.41K 10-K · filed 2026-03-12 |
| 2025-09-30 | $8.12K 10-Q · filed 2025-11-12 | $12.98K derived: sum of 2 quarters · filed 2026-08-13 | -$11.83K 10-Q · filed 2025-11-12 | -$829.76K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.87K 10-Q · filed 2026-08-13 | -$19.95K 10-Q · filed 2026-08-13 | -$837.88K derived: sum of 3 quarters · filed 2026-08-13 | -$1.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$24.81K 10-Q · filed 2026-05-14 | -$842.74K derived: sum of 2 quarters · filed 2026-05-14 | -$1.32M derived: sum of 3 quarters · filed 2026-05-14 | -$1.27M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$817.93K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.29M derived: sum of 2 quarters · filed 2026-03-12 | -$1.24M derived: sum of 3 quarters · filed 2026-03-12 | -$1.25M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$474.57K 10-Q · filed 2025-11-12 | -$425.03K derived: sum of 2 quarters · filed 2025-11-12 | -$429.38K 10-Q · filed 2025-11-12 | -$431.79K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $49.54K 10-Q · filed 2025-08-14 | $45.19K 10-Q · filed 2025-08-14 | $42.78K derived: sum of 3 quarters · filed 2025-08-14 | $40.40K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$4.35K 10-Q · filed 2025-05-19 | -$6.76K derived: sum of 2 quarters · filed 2025-05-19 | -$9.14K derived: sum of 3 quarters · filed 2025-05-19 | -$11.49K derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | -$2.41K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08 | -$4.79K derived: sum of 2 quarters · filed 2025-04-08 | -$7.14K derived: sum of 3 quarters · filed 2025-04-08 | -$9.46K 10-K · filed 2025-04-08 |
| 2023-09-30 | -$2.38K 10-Q · filed 2024-11-14 | -$4.73K derived: sum of 2 quarters · filed 2024-11-14 | -$7.05K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$2.35K 10-Q · filed 2024-08-13 | -$4.67K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |